Triglav Skladi D.O.O. Purchases Shares of 18,027 Biogen Inc. (NASDAQ:BIIB)

Triglav Skladi D.O.O. acquired a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,027 shares of the biotechnology company's stock, valued at approximately $2,756,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 141 shares during the period. Lee Danner & Bass Inc. bought a new position in Biogen during the 4th quarter valued at $25,000. Colonial Trust Co SC boosted its stake in Biogen by 9,300.0% during the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 186 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Biogen during the 4th quarter valued at $32,000. Finally, SRS Capital Advisors Inc. acquired a new stake in shares of Biogen during the 4th quarter valued at $33,000. 87.93% of the stock is owned by institutional investors.

Biogen Price Performance

Shares of NASDAQ:BIIB traded down $0.52 during trading on Thursday, reaching $126.30. The stock had a trading volume of 937,000 shares, compared to its average volume of 1,392,698. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The stock has a market capitalization of $18.51 billion, a PE ratio of 11.29, a P/E/G ratio of 1.51 and a beta of 0.12. The business's 50-day moving average price is $125.30 and its 200 day moving average price is $141.60. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). The company had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The business's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the business earned $3.67 EPS. As a group, equities analysts predict that Biogen Inc. will post 15.83 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on BIIB shares. Sanford C. Bernstein started coverage on Biogen in a research report on Tuesday, February 11th. They set a "market perform" rating and a $160.00 price objective for the company. Needham & Company LLC restated a "hold" rating on shares of Biogen in a report on Friday, May 2nd. Oppenheimer set a $205.00 target price on Biogen in a report on Friday, May 2nd. Hsbc Global Res lowered Biogen from a "strong-buy" rating to a "hold" rating in a report on Monday, April 28th. Finally, Wells Fargo & Company cut their price objective on Biogen from $165.00 to $140.00 and set an "equal weight" rating for the company in a report on Thursday, February 13th. Twenty investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Biogen currently has an average rating of "Hold" and a consensus price target of $191.30.

Insider Buying and Selling at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the completion of the sale, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.